Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000595181 | SCV000708778 | uncertain significance | not provided | 2017-05-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000814022 | SCV000954410 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2E | 2021-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid with asparagine at codon 281 of the SGCB protein (p.Asp281Asn). The aspartic acid residue is weakly conserved and there is a small physicochemical difference between aspartic acid and asparagine. This variant is present in population databases (rs374923265, ExAC 0.04%). This missense change has been observed in individual(s) with limb-girdle muscular dystrophy (PMID: 28687063). ClinVar contains an entry for this variant (Variation ID: 502151). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The asparagine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV000595181 | SCV001715838 | uncertain significance | not provided | 2019-12-16 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000814022 | SCV002082969 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2E | 2020-03-19 | no assertion criteria provided | clinical testing |